Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Charact-IL-2: Low-dose IL-2 in SLE
NCT03312335Phase 2Completed
- Start
- Aug 2018
- Primary completion
- Dec 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in systemic lupus erythematosus (SLE). Started Aug 2018; status: completed.
02
Drugs
aldesleukin
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03312335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03312335.